Literature DB >> 19467887

Association between tumor necrosis factor alpha 308G/A polymorphism and increased proinflammatory cytokine release after cardiac surgery with cardiopulmonary bypass in the Korean population.

Seung Zhoo Yoon1, In-Jin Jang, Yoon Ji Choi, Mae Hwa Kang, Hye Ja Lim, Young Jin Lim, Hye Won Lee, Seong Ho Chang, Suk Min Yoon.   

Abstract

OBJECTIVES: The G-308A polymorphism of the tumor necrosis factor alpha (TNF-alpha) gene has been suggested to be linked to high TNF promoter activity in in vitro studies. However, there have been some controversies in in vivo studies. This study investigated whether A allele at TNF-308 site is associated with (1) the changes in plasma cytokine levels during and after cardiopulmonary bypass (CPB) and (2) an increased incidence of pulmonary morbidity after CPB.
DESIGN: Prospective and observational investigation.
SETTING: A university hospital, single institution. PARTICIPANTS: Patients scheduled for cardiac surgery with CPB. INTERVENTION: TNF genotype was determined by the real-time polymerase chain reaction method. IL-6 and TNF-alpha levels were measured by enzyme-linked immunosorbent assay at the following time points: T1, before initiation of CPB; T2, 30 minutes of CPB; T3, 30 minutes after CPB; T4, 2 hours after CPB; and T5, 24 hours after CPB. The oxygen index, serum creatinine level, 24-hour blood loss, intubation time, and length of intensive care unit (ICU) stay were examined.
MEASUREMENTS AND MAIN RESULTS: The levels of TNF-alpha in group A (TNF-308GA/AA, n = 25) were higher at T3, T4, and T5 than group G (TNF-308GG, n = 225). The levels of IL-6 showed no statistical difference. The oxygenation index, serum creatinine level, 24-hour blood loss, intubation time, and length of ICU stay showed no statistical difference.
CONCLUSIONS: TNF G-308A polymorphism may be associated with excess TNF-alpha secretion in this study and may not be associated with excess IL-6 secretion and postoperative morbidity after CPB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467887     DOI: 10.1053/j.jvca.2009.03.004

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  6 in total

1.  TNF-α-308G/A polymorphism associated with TNF-α protein expression in patients with diabetic nephropathy.

Authors:  Yan Peng; Liu-Juan Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Inflammatory single nucleotide polymorphisms and the risk of atrial fibrillation: a case control study.

Authors:  Kristoffer M Henningsen; Morten S Olesen; Lasse S Ravn; Ulrik Dixen; Stig Haunsoe; Helle Bruunsgaard; Jesper H Svendsen
Journal:  Inflamm Res       Date:  2010-12-04       Impact factor: 4.575

3.  Single nucleotide polymorphisms in inflammatory genes and the risk of early onset of lone atrial fibrillation.

Authors:  Kristoffer M A Henningsen; Morten S Olesen; Maria Pedersen; Lone Nielsen; Stig Haunsø; Helle Bruunsgaard; Jesper Hastrup Svendsen
Journal:  Inflamm Res       Date:  2010-05-20       Impact factor: 4.575

4.  Impact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients.

Authors:  Jung-Woo Chae; Terence Ng; Hui Ling Yeo; Maung Shwe; Yan Xiang Gan; Han Kiat Ho; Alexandre Chan
Journal:  PLoS One       Date:  2016-10-04       Impact factor: 3.240

5.  Association of genetic polymorphisms with acute kidney injury after cardiac surgery in a Southeast Asian population.

Authors:  Kah Ming Eddy Saw; Rui Ge Roderica Ng; Siew Pang Chan; Yi Hui Ang; Lian Kah Ti; Tsong Huey Sophia Chew
Journal:  PLoS One       Date:  2019-04-11       Impact factor: 3.240

6.  Blood cytokine expression correlates with early multi-organ damage in a mouse model of moderate hypothermia with circulatory arrest using cardiopulmonary bypass.

Authors:  Ruslan Natanov; Faikah Gueler; Christine S Falk; Christian Kühn; Ulrich Maus; Erin C Boyle; Thierry Siemeni; Ann-Katrin Knoefel; Serghei Cebotari; Axel Haverich; Nodir Madrahimov
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.